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Background
Individuals with spina bifida (SB) are at risk for deteriora-
tion of their upper urinary tracts due to neurogenic blad-
der and subsequent progressive chronic renal
insufficiency (CRI). Serum creatinine (SCr) is the most
widely used marker to assess renal function and to esti-
mate glomerular filtration rate (GFR), although it has sig-
nificant limitations. SCr is dependent on age, height,
gender and muscle mass and has been shown to be an
unreliable marker of renal function in SB. Cystatin C
(CyC) is a cysteine proteinase inhibitor of low molecular
weight, produced at a constant rate by all nucleated cells,
freely filtered at the glomerulus, and not secreted or reab-
sorbed at the renal tubule. CyC is independent of age,
height, and gender and is believed to be independent of
muscle mass. Over the past several years, serum CyC has
been shown to be a better marker of renal function and
GFR than SCr (using the Schwartz formula) in children.
One study by Pham-Huy in 2003 showed that CyC was
much better correlated with GFR than SCr in children
with SB.
Materials and methods
We made arrangements with the Johns Hopkins Hospital
Department of Laboratory Medicine to make Cystatin C
available as a clinical laboratory test and began recom-
mending yearly Cystatin C and serum electrolytes as part
of routine care for patients in the SB Center at Kennedy
Krieger Institute in July 2006.
Results
To date, CyC has been measured in 34 patients, mean age
of 18.2 years, and range 1 to 47. None of these patients
were previously diagnosed with CRI. For 33 of the patients
with SB, the CyC measurements were within the previ-
ously established normal range for children and adults of
0.5 – 1.0 mg/L. These 33 SB patients had a mean CyC of
0.75 mg/L, range 0.56 to 0.94, and standard deviation of
0.10, fitting a very typical normal distribution. The 47 year
old had an elevated CyC of 1.91 mg/dL, suggesting CR.
Review of her history showed several episodes of acute
renal failure in the past as well as chronic metabolic aci-
dosis and other clinical evidence of CRI, although her
measured serum creatinine was normal at 1.0 mg/dL. Of
the 33 patients, 19 (58%) had SCr measured below nor-
mal while CyC was always within the normal range. One
patient had CyC measured twice, 6 months apart, and val-
ues were consistent 0.81 initially and then 0.85.
Conclusion
Cystatin C shows promise as a simple blood test that can
be used to screen individuals with SB for early develop-
ment of chronic renal insufficiency and for estimating
GFR.
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